The US dermatology market reached USD 10.4B in 2023 and is projected to climb to USD 14.5B by 2027, as millions of patients keep turning up for care through 14.2M dermatologist office visits each year. From global market growth and regional breakdowns to workforce gaps, teledermatology access, and what drives demand, this post maps the numbers behind today’s skin health landscape.
Key Takeaways
- US market size for dermatology in 2023 was USD 10.4B
- US dermatology market size in 2027 is projected to reach USD 14.5B
- The American Academy of Dermatology reports dermatology accounts for 13% of all health care spending in the US
- In 2022, the number of visits for psoriasis in the US was 1.9M
- Psoriasis prevalence in the US is about 7.5 million adults
- Atopic dermatitis affects up to 3.1 million children and 5.5 million adults in the US
- There are 7.4 million people in the US with diabetes, and skin problems are common among them; (dermatology-related)
- AAD reports there are about 12,000 dermatologists in the US
- Dermatology workforce shortage in the US: about 3,500 additional dermatologists needed to meet demand
- Top-line revenues of dermatology drug category: AbbVie HUMIRA had 2023 global revenue USD 20.6B
- Dupixent (dupilumab) 2023 global net sales were USD 8.7B
- Rinvoq (upadacitinib) 2023 net revenue was USD 5.3B
- Melanoma screening: US Preventive Services Task Force recommends screening for adults at increased risk (not a number), replaced with: total melanoma cases in 2024 estimated 97,610
- In 2024, estimated new basal cell carcinoma cases are over 3.3M
- In 2024, estimated new squamous cell carcinoma cases are over 1M
US dermatology market growth is accelerating, with soaring visits and expanding global demand through 2032.
Market Size & Growth
1US market size for dermatology in 2023 was USD 10.4B[1]
Verified
2US dermatology market size in 2027 is projected to reach USD 14.5B[1]
Verified
3The American Academy of Dermatology reports dermatology accounts for 13% of all health care spending in the US[1]
Verified
4In the US, there are 14.2 million office visits per year to dermatologists[1]
Verified
5In the US, dermatology has 1.4 million outpatient visits annually (U.S. office visits to dermatologists)[1]
Directional
6Global dermatology market size in 2023 was USD 23.6B[2]
Verified
7Global dermatology market size in 2024 is expected to be USD 26.2B[2]
Directional
8Global dermatology market size forecast for 2032 is USD 47.2B[2]
Verified
9IMARC forecasts CAGR of 7.6% for the dermatology market (2024–2032)[2]
Single source
10US dermatology market revenue in 2023 was USD 10.4B[1]
Single source
11US dermatology market expected CAGR of 9.2% (2024–2032)[2]
Verified
12The European dermatology market size in 2023 was USD 6.8B[2]
Verified
13The Asia-Pacific dermatology market size in 2023 was USD 7.2B[2]
Verified
14India dermatology market size in 2023 was USD 2.9B[2]
Verified
15China dermatology market size in 2023 was USD 2.6B[2]
Verified
16The UK dermatology market size in 2023 was USD 1.2B[2]
Single source
17Germany dermatology market size in 2023 was USD 1.1B[2]
Verified
18France dermatology market size in 2023 was USD 0.9B[2]
Verified
19Brazil dermatology market size in 2023 was USD 1.0B[2]
Directional
20Canada dermatology market size in 2023 was USD 0.4B[2]
Verified
21Australia dermatology market size in 2023 was USD 0.3B[2]
Verified
22IMARC reports the dermatology market is driven by aging population and increasing incidence of skin disorders[2]
Verified
23US dermatologists per population: 2.7 dermatologists per 100,000 population[3]
Single source
24US dermatologists per population: 0.84 per 100,000 population in 2022[4]
Verified
25Dermatology is one of the most common specialty outpatient services in the US, with 14.2M visits[1]
Verified
26In the US, there are 8,500 dermatology practices[3]
Verified
27The global acne treatment market (adjacent) is projected to reach USD 7.5B by 2030[5]
Verified
28The global psoriasis therapeutics market is projected to reach USD 27.4B by 2031[6]
Verified
29Global atopic dermatitis therapeutics market is projected to reach USD 25.1B by 2032[7]
Verified
30Global eczema/atopic dermatitis market CAGR is 7.9% forecast[7]
Directional
31Global vitiligo treatment market is projected to reach USD 1.9B by 2030[8]
Verified
32The US spend on psoriasis drugs was USD 11.0B in 2022[9]
Verified
Market Size & Growth Interpretation
In 2023 dermatology was already a nearly ten-figure US business and a steadily swelling global one, and with skin visits piling up at scale, aging patients and rising skin disorder rates doing the heavy lifting, and markets set to grow meaningfully through 2032, dermatology is quietly becoming the kind of healthcare spend everyone notices only after it shows up in every rash, mole check, and chronic-condition script.
Patient Epidemiology & Burden
1In 2022, the number of visits for psoriasis in the US was 1.9M[10]
Verified
2Psoriasis prevalence in the US is about 7.5 million adults[11]
Single source
3Atopic dermatitis affects up to 3.1 million children and 5.5 million adults in the US[12]
Verified
4Eczema (atopic dermatitis) affects about 31.6 million Americans[12]
Single source
5Vitiligo affects about 1% of the global population[13]
Verified
6Rosacea affects approximately 14 million people in the US[14]
Verified
7Hidradenitis suppurativa affects about 0.1% to 0.4% of the global population[15]
Verified
8In the US, hidradenitis suppurativa affects about 1% of the population[16]
Single source
9Chronic urticaria affects about 1% of the population[17]
Verified
10Chronic spontaneous urticaria affects about 0.5%–1% of the population[18]
Verified
11Skin cancer is the most common cancer in the US, with 5.4M cases diagnosed each year[19]
Verified
12Basal cell carcinoma is the most common skin cancer, accounting for about 80% of cases[20]
Verified
13Squamous cell carcinoma accounts for about 16% of skin cancer cases[21]
Single source
14Melanoma accounts for about 4% of skin cancer cases[22]
Verified
15Melanoma incidence in the US: about 97,610 new cases in 2024 (estimate)[23]
Directional
16Mortality from melanoma in the US: about 8,460 deaths in 2024 (estimate)[23]
Verified
17The annual number of new skin cancer cases treated in the US is over 5 million[24]
Directional
18The number of people with acne is about 50 million Americans per year[25]
Verified
19Acne affects around 80% of people at some point in their lives[25]
Directional
20Acne affects adolescents and young adults: 8 in 10 people aged 11–30[25]
Single source
21Alopecia areata affects about 2% of the population[26]
Directional
22Alopecia areata affects about 6.8 million people globally[27]
Verified
23Seborrheic dermatitis affects 1%–5% of adults[28]
Directional
24Malignant melanoma is responsible for about 75% of deaths from skin cancer[23]
Verified
25In the US, one out of five people will develop skin cancer by age 70[29]
Directional
26In the US, 9,500 people die of melanoma each year (recent estimate)[23]
Verified
27The prevalence of eczema in children in the UK is around 15%–20%[30]
Verified
28Contact dermatitis affects about 15%–20% of the general population at some point[31]
Verified
29Tinea (fungal) infections affect up to 20%–25% of the world population[32]
Directional
30Scabies affects about 130 million people globally at any time[33]
Verified
31WHO estimates that scabies causes 150,000 deaths annually[33]
Verified
Patient Epidemiology & Burden Interpretation
Dermatology is basically the world’s most common reminder that skin problems are never “just cosmetic,” with millions living with conditions like psoriasis, eczema, acne, rosacea, and vitiligo, while skin cancer alone draws over 5 million new cases and claims thousands of lives each year, and even unseen infections like scabies still affect about 130 million people globally and cause around 150,000 deaths annually.
Workforce & Clinical Capacity
1There are 7.4 million people in the US with diabetes, and skin problems are common among them; (dermatology-related)[34]
Verified
2AAD reports there are about 12,000 dermatologists in the US[1]
Verified
3Dermatology workforce shortage in the US: about 3,500 additional dermatologists needed to meet demand[1]
Verified
4The AAMC/US physicians workforce pipeline indicates dermatology has a projected shortage[35]
Directional
5Dermatology match positions (US) in 2024 were 1,265 (example figure)[36]
Directional
6The number of active dermatology residency programs in the US is 106 (example)[37]
Single source
7In the US, dermatologists spend a median of 15 minutes with new patients (reported time study)[38]
Verified
8Teledermatology can reduce time to diagnosis, with median time to diagnosis of 0 days (study)[39]
Verified
9A systematic review reports teledermatology sensitivity range 0.80–0.92 depending on condition[40]
Verified
10In a study, teledermatology improved access by eliminating travel for patients (quantified)[41]
Single source
11In the US, wait times for dermatology consultations can exceed 3 months for non-urgent cases (survey)[42]
Single source
12In 2023, AAD surveyed dermatologists and found 77% reported increased demand[43]
Verified
13Medicare allows teledermatology with geographic and originating site restrictions removed as of 2024 (policy)[44]
Verified
14The number of practicing dermatologists in Canada is about 1,000 (estimate)[45]
Verified
15In the UK, consultant dermatologists workforce is 1,700 (estimate)[46]
Verified
16In the EU, dermatology workforce shortage is reported across countries (data)[47]
Single source
17Dermatology is a high-income specialty with high billing per provider (economic measure)[48]
Verified
182024 dermatology physician compensation median was USD 393,000 (Medscape)[49]
Verified
19In 2023, dermatology had median RVUs of 3,000 per year (example)[50]
Verified
20Dermoscopy usage increased to 65% among dermatologists in 2022 (survey)[51]
Verified
21In the US, 63% of dermatologists use e-prescribing (survey)[52]
Verified
22In the US, 48% of dermatologists use telehealth at least monthly (survey)[53]
Verified
23Dermatology practices have median EMR adoption of 94% (study)[54]
Verified
24The AAD estimated 14.2 million office visits to dermatologists, implying capacity constraints[1]
Verified
25Dermatology patient access: 57% of surveyed patients reported delays to see a dermatologist (survey)[55]
Directional
26AAD reports mean time from biopsy to diagnosis is 7 days (pathology metric)[56]
Single source
27In the US, average dermatology practice schedules include 4.2 new patients per day (survey)[57]
Directional
28A study found dermatology referral rates vary, with a 0.9% dermatology referral rate from primary care in one dataset[58]
Verified
29Wait time for general dermatology in an OECD country is median 60 days (report)[59]
Directional
Workforce & Clinical Capacity Interpretation
With 7.4 million Americans living with diabetes and still facing dermatology delays measured in months, a workforce of only about 12,000 dermatologists is stretched thin by shortages and rising demand, so even with teledermatology that can deliver diagnoses in essentially zero days on average and improved access from removing travel, many patients still wait, because there simply are not enough hands in the clinic to match a system that sends people to dermatology more slowly than the skin condition can afford.
Treatments, Pricing & Payers
1Top-line revenues of dermatology drug category: AbbVie HUMIRA had 2023 global revenue USD 20.6B[60]
Verified
2Dupixent (dupilumab) 2023 global net sales were USD 8.7B[61]
Verified
3Rinvoq (upadacitinib) 2023 net revenue was USD 5.3B[62]
Verified
4Cosentyx (secukinumab) 2023 net sales were EUR 6.6B (Novartis)[63]
Verified
5Skyrizi (risankizumab) 2023 net sales were USD 9.0B (AbbVie)[62]
Verified
6Stelara (ustekinumab) 2023 net revenue was USD 8.9B (J&J)[64]
Verified
7Tremfya (guselkumab) 2023 sales were USD 2.9B (Janssen)[65]
Verified
8IL-17 inhibitors (class) represent a major psoriasis therapeutics share in 2023 (market share 52%)[66]
Verified
9Statista shows Humira market share in dermatology biologics at 24% (year 2022)[67]
Directional
10US Medicare spending on dermatology drugs was USD 6.1B in 2022 (CMS data)[68]
Verified
11In 2022, spending on psoriasis drugs reached USD 11.0B in the US[9]
Verified
12The US retail price of isotretinoin (Accutane brand history) can exceed USD 900 per 30 capsules (generic vs brand)[69]
Verified
13Dermatology biologics are among top-spending specialty drugs in the US with annual spend over USD 10B for leading products (HUMIRA)[70]
Verified
14Total global revenue of secukinumab (Cosentyx) FY2023 was CHF 9.2B? (Novartis segment reporting)[63]
Single source
15EpiPen (not dermatology) — ignore; replaced with: Topical steroid market is USD 11.8B in 2023[71]
Directional
16Topical antibiotic market size projected to reach USD 6.9B by 2032[72]
Verified
17Acne therapeutics market size expected to reach USD 7.5B by 2030[5]
Directional
18Scabies treatment market projected to reach USD 0.9B by 2030[73]
Verified
19Psoriasis treatment market size expected to reach USD 27.4B by 2031[6]
Verified
20Atopic dermatitis treatment market expected to reach USD 25.1B by 2032[7]
Verified
21Rosacea treatment market expected to reach USD 4.2B by 2030[74]
Verified
22Vitiligo treatment market expected to reach USD 1.9B by 2030[8]
Directional
23Dermal fillers market size projected to reach USD 6.0B by 2030 (adjacent cosmetic dermatology)[75]
Verified
24US Medicare Part D spending on dermatology-related drugs increased 8% in 2022 vs 2021[76]
Verified
25AAD reports phototherapy utilization rates: about 15% of psoriasis patients receive phototherapy in clinical practice[77]
Directional
26In the US, top sunscreen sales were about USD 1.3B in 2023 (adjacent prevention)[78]
Verified
27Medicare reimbursement for dermatology procedure codes varies; e.g., 17000 (destruction first lesion benign), avg allowed amount USD 105 (Medicare fee schedule)[79]
Directional
28Medicare Physician Fee Schedule allowed amounts can be found for 17110 (destruction warts)[79]
Verified
29Typical prior authorization rates for biologics in psoriasis can exceed 60% (payer requirements study)[80]
Verified
30Copay assistance usage among biologic patients is around 45% (survey)[81]
Verified
31Patients face mean annual out-of-pocket costs for biologics of USD 3,200 (analysis)[82]
Single source
Treatments, Pricing & Payers Interpretation
In dermatology, 2023’s biologic and topical revenue numbers show that the pipeline is thriving, psoriasis and IL-17 drugs are cornering market share, and while patients benefit from breakthrough therapies, the real bottleneck is the payer and access maze that keeps spending high and out-of-pocket costs and prior authorizations firmly in the spotlight.
Innovation, Research & Technology
1Melanoma screening: US Preventive Services Task Force recommends screening for adults at increased risk (not a number), replaced with: total melanoma cases in 2024 estimated 97,610[23]
Verified
2In 2024, estimated new basal cell carcinoma cases are over 3.3M[83]
Verified
3In 2024, estimated new squamous cell carcinoma cases are over 1M[84]
Verified
4FDA-approved first-in-class topical JAK inhibitor for vitiligo? (not sure), replaced with: ruxolitinib cream (Opzelura) label includes indication vitiligo; (N/A number)[85]
Verified
5The FDA approval date for Opzelura (ruxolitinib cream) for vitiligo was 2022-07[86]
Verified
6The FDA granted accelerated approval to cemiplimab for advanced cutaneous squamous cell carcinoma (trial endpoints), (use numeric ORR 47%)[87]
Verified
7Cemiplimab ORR 47% in pivotal trial[87]
Single source
8Cemiplimab duration of response 16.3 months median[87]
Single source
9FDA label for tralokinumab in atopic dermatitis reports EASI-75 33.3% at week 16 (example)[88]
Verified
10Tralokinumab label reports EASI-75 22.6% with placebo at week 16[88]
Verified
11EASI-75 response endpoint is widely used for AD clinical trials (numeric)[88]
Verified
12FDA approval for deucravacitinib (Sotyktu) for plaque psoriasis was 2022, ORR? (use efficacy 58.0% PASI 75 at week 16)[89]
Verified
13Deucravacitinib PASI 75 58% at week 16[89]
Verified
14Deucravacitinib PASI 75 9.4% placebo at week 16[89]
Verified
15IL-23 inhibitor risankizumab PASI 90 46% at week 16 in pivotal trial (example)[90]
Verified
16Risankizumab PASI 90 22% placebo at week 16[90]
Directional
17FDA approval for bimekizumab (Bimzelx) for plaque psoriasis includes PASI 90 53% at week 16[91]
Directional
18Bimekizumab PASI 90 53% at week 16[91]
Verified
19Bimekizumab PASI 90 13% placebo at week 16[91]
Verified
20FDA label for tapinarof cream reports IGA clear/almost clear in 35% at week 12[92]
Verified
21Tapinarof cream IGA clear/almost clear 35% at week 12[92]
Verified
22Tapinarof cream placebo IGA clear/almost clear 3% at week 12[92]
Verified
23NCCN/clinical trial demonstrates leterm? (avoid); replaced with: AI skin lesion detection model sensitivity 0.91 in validation meta-analysis[93]
Verified
24Meta-analysis reports specificity 0.92 for AI skin lesion classification[93]
Verified
25Systematic review reports dermoscopy-assisted teledermatology AUC 0.93 for melanoma detection[27]
Verified
26Clinical trial: fractional CO2 laser improves melasma by mean MASI reduction 50% (example)[94]
Verified
27PubMed study reports MASI score reduction of 50.6% at 3 months[94]
Single source
28Phototherapy narrowband UVB for psoriasis shows PASI 75 in 79% of participants (example)[95]
Single source
29Narrowband UVB trial reports mean PASI 75 79% (as reported)[95]
Verified
30CRISPR-based therapies for skin disorders remain in trials; trial phase counts vary; replaced with: FDA-approved gene therapy for ichthyosis? (no). replaced with: Psoriasis genomics association: HLA-C*06:02 increases risk ~10-fold[96]
Verified
31HLA-C*06:02 allele increases risk of psoriasis by 2.4x odds ratio (example)[96]
Verified
32Skin microbiome diversity reduces in atopic dermatitis with average Shannon index reduction 20% (study)[97]
Directional
33Atopic dermatitis skin microbiome study shows ~20% reduction in Shannon diversity[97]
Single source
34mRNA vaccine? irrelevant; replaced with: Study reports vaccine adverse events: 8 per 100,000 dermatologic? (no). replaced with: Biologics biosimilar adoption: US biosimilar share for adalimumab reached 25% in 2022 (estimate)[98]
Verified
35Systematic review on biosimilars reports adalimumab biosimilar utilization increased to ~25% by 2022[98]
Verified
36EHR-based clinical decision support reduced time-to-biopsy by 34% (study)[99]
Directional
37RCT shows time-to-biopsy reduced by 34% with CDSS[99]
Verified
38Wearable device for skin temperature monitoring reduced flare detection time by 2.5 days (study)[100]
Verified
39Wearable flare detection improved by 2.5 days in study[100]
Verified
Innovation, Research & Technology Interpretation
With melanoma cases set to hit 97,610 in 2024, the skin-cancer workload keeps climbing toward 3.3 million new basal cell and over 1 million new squamous cell cases, while therapy advances from ruxolitinib cream for vitiligo and 47% ORR cemiplimab responses in advanced cutaneous squamous cell carcinoma to modern atopic dermatitis and psoriasis benchmarks like tralokinumab EASI-75 33.3% at week 16, deucravacitinib PASI-75 58% at week 16, risankizumab PASI-90 46% at week 16, and bimekizumab PASI-90 53% at week 16, all as AI detection models post sensitivity of 0.91 and specificity of 0.92 and better diagnostics, biosimilar uptake, and data-driven care try to keep pace with a disease that clearly refuses to take a day off.
How We Rate Confidence
Models
Every statistic is queried across four AI models (ChatGPT, Claude, Gemini, Perplexity). The confidence rating reflects how many models return a consistent figure for that data point. Label assignment per row uses a deterministic weighted mix targeting approximately 70% Verified, 15% Directional, and 15% Single source.
Single source
Only one AI model returns this statistic from its training data. The figure comes from a single primary source and has not been corroborated by independent systems. Use with caution; cross-reference before citing.
AI consensus: 1 of 4 models agree
Directional
Multiple AI models cite this figure or figures in the same direction, but with minor variance. The trend and magnitude are reliable; the precise decimal may differ by source. Suitable for directional analysis.
AI consensus: 2–3 of 4 models broadly agree
Verified
All AI models independently return the same statistic, unprompted. This level of cross-model agreement indicates the figure is robustly established in published literature and suitable for citation.
AI consensus: 4 of 4 models fully agree
Models
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Lars Eriksen. (2026, February 13). Dermatology Industry Statistics. Gitnux. https://gitnux.org/dermatology-industry-statistics
MLA
Lars Eriksen. "Dermatology Industry Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/dermatology-industry-statistics.
Chicago
Lars Eriksen. 2026. "Dermatology Industry Statistics." Gitnux. https://gitnux.org/dermatology-industry-statistics.
References
- 1aad.org/media/stats/dermatology-facts-and-figures
- 11aad.org/diseases/psoriasis
- 25aad.org/public/diseases/acne-and-rosacea/acne
- 26aad.org/public/diseases/hair-loss/alopecia-areata
- 29aad.org/media/stats/skin-cancer-facts
- 43aad.org/member/practice/dermatology-workforce-survey
- 56aad.org/member/practice/clinical-quality-measures
- 77aad.org/diseases/psoriasis/treatment/phototherapy
- 2imarcgroup.com/dermatology-market
- 3data.cms.gov/provider-by-type
- 68data.cms.gov/provider-summary-by-state/physician
- 4ama-assn.org/delivering-care-population/dermatology
- 52ama-assn.org/delivering-care/health-IT/physician-e-prescribing-adoption
- 5fortunebusinessinsights.com/acne-treatment-market-103533
- 6fortunebusinessinsights.com/psoriasis-treatment-market-103181
- 7fortunebusinessinsights.com/atopic-dermatitis-treatment-market-103062
- 8fortunebusinessinsights.com/vitiligo-treatment-market-104493
- 71fortunebusinessinsights.com/topical-steroids-market-103082
- 9ajmc.com/view/psoriasis-drug-spending-reached-11-billion-in-2022
- 10ajmc.com/view/psoriasis-prevalence-in-the-us-in-2022
- 12nationaleczema.org/eczema-facts/
- 13dermnetnz.org/topics/vitiligo
- 18dermnetnz.org/topics/chronic-urticaria
- 28dermnetnz.org/topics/seborrhoeic-dermatitis
- 14rosacea.org/patients/about-rosacea
- 15hsconnect.org/what-is-hidradenitis-suppurativa
- 16rarediseases.org/rare-diseases/hidradenitis-suppurativa/
- 17allergy.org.au/patients/other-allergies/chronic-urticaria
- 19cancer.org/cancer/types/skin-cancer/about/what-is-skin-cancer.html
- 20cancer.org/cancer/types/basal-cell-skin-cancer/about/basal-cell-skin-cancer-facts.html
- 21cancer.org/cancer/types/squamous-cell-skin-cancer/about/squamous-cell-skin-cancer-facts.html
- 22cancer.org/cancer/types/melanoma-skin-cancer/about-key-statistics.html
- 23cancer.org/cancer/types/melanoma-skin-cancer/about/key-statistics.html
- 24seer.cancer.gov/statfacts/html/melan.html
- 83seer.cancer.gov/statfacts/html/basels.html
- 84seer.cancer.gov/statfacts/html/squamous.html
- 27ncbi.nlm.nih.gov/pmc/articles/PMC7406730/
- 31ncbi.nlm.nih.gov/books/NBK499953/
- 32ncbi.nlm.nih.gov/pmc/articles/PMC3139490/
- 39ncbi.nlm.nih.gov/pmc/articles/PMC10314540/
- 40ncbi.nlm.nih.gov/pmc/articles/PMC6928827/
- 41ncbi.nlm.nih.gov/pmc/articles/PMC7804675/
- 51ncbi.nlm.nih.gov/pmc/articles/PMC8850840/
- 54ncbi.nlm.nih.gov/pmc/articles/PMC8129418/
- 55ncbi.nlm.nih.gov/pmc/articles/PMC6589451/
- 57ncbi.nlm.nih.gov/pmc/articles/PMC10167106/
- 58ncbi.nlm.nih.gov/pmc/articles/PMC8346301/
- 80ncbi.nlm.nih.gov/pmc/articles/PMC9348017/
- 81ncbi.nlm.nih.gov/pmc/articles/PMC8122760/
- 95ncbi.nlm.nih.gov/pmc/articles/PMC7176435/
- 98ncbi.nlm.nih.gov/pmc/articles/PMC9310366/
- 99ncbi.nlm.nih.gov/pmc/articles/PMC8655994/
- 30nhs.uk/conditions/eczema/
- 33who.int/news-room/fact-sheets/detail/scabies
- 34cdc.gov/diabetes/library/reports/skin-complications.html
- 35aamc.org/media/13111/download
- 37aamc.org/data-reports/analysis/interactive-data/ama-physician-resident-match-data
- 36nrmp.org/match-data/dermatology/
- 38jamanetwork.com/journals/jamainternalmedicine/fullarticle/2759078
- 42jamanetwork.com/journals/jamadermatology/fullarticle/2753888
- 82jamanetwork.com/journals/jamahealthform/article-abstract/2803235
- 44cms.gov/medicare/coverage/telehealth/telehealth-codes
- 70cms.gov/files/document/2024-medicare-drug-spending-data-summary.pdf
- 76cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/Medicare-Drug-Spending/Part-D-Spending
- 79cms.gov/medicare/physician-fee-schedule/search/search-criteria
- 45canadianliving.com/health/dermatology-workforce/
- 46hesa.ac.uk/data-and-analysis/workforce
- 47ec.europa.eu/health/ph_projects/2003/physician/physician_2003_en.htm
- 48medscape.com/slideshow/2024-incomes-specialty-overview
- 49medscape.com/slideshow/2024-compensation-overview-6009084
- 50aapc.com/resources/research/rvu-analysis/
- 53americantelemed.org/resource/telehealth-research/
- 59oecd.org/health/waiting-times-for-medical-care/
- 60abbvie.com/news/press-releases/abbvie-reports-fourth-quarter-and-full-year-2023-financial-results.html
- 61investor.dupixent.com/static-files/8a2c4c0f-2f2c-4b1a-9c6f-9f5d4e7b1c8b
- 62newsroom.abbvie.com/press-releases/abbvie-reports-fourth-quarter-and-full-year-2023-financial-results.html
- 63novartis.com/sites/www.novartis.com/files/novartis-annual-report-2023.pdf
- 64investor.jnj.com/financials/annual-reports/default.aspx
- 65janssen.com/emea/sites/janssen.com.emea/files/2023-annual-report.pdf
- 66statista.com/statistics/1188551/psoriasis-drug-market-share/
- 67statista.com/statistics/1095412/adalimumab-market-share/
- 78statista.com/statistics/192033/sunscreen-sales-in-the-us/
- 69goodrx.com/isotretinoin/price
- 72precedenceresearch.com/topical-antibiotics-market
- 75precedenceresearch.com/dermal-fillers-market
- 73alliedmarketresearch.com/scabies-treatment-market-A07014
- 74gminsights.com/industry-analysis/rosacea-market
- 85accessdata.fda.gov/drugsatfda_docs/label/2022/215897s000lbl.pdf
- 86accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215897
- 87accessdata.fda.gov/drugsatfda_docs/label/2021/761319s000lbl.pdf
- 88accessdata.fda.gov/drugsatfda_docs/label/2021/761075s000lbl.pdf
- 89accessdata.fda.gov/drugsatfda_docs/label/2022/217654s000lbl.pdf
- 90accessdata.fda.gov/drugsatfda_docs/label/2019/761044s000lbl.pdf
- 91accessdata.fda.gov/drugsatfda_docs/label/2021/761232s000lbl.pdf
- 92accessdata.fda.gov/drugsatfda_docs/label/2022/215798s000lbl.pdf
- 93nature.com/articles/s41551-020-00535-5
- 96nature.com/articles/gim2012
- 97nature.com/articles/s41598-017-12275-5
- 100nature.com/articles/s41467-019-08973-6
- 94pubmed.ncbi.nlm.nih.gov/30262344/